News >

TKI Discontinuation Safe in CML, But Patient Selection Is Key

Caroline Seymour
Published: Wednesday, May 01, 2019

Martha Wadleigh, MD

Martha Wadleigh, MD

Although TKIs have significantly improved life expectancy for patients with chronic myeloid leukemia (CML), investigators are actively examining ways to safely discontinue treatment without sacrificing benefit. To effectively do this, patient selection is key, said Martha Wadleigh, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication